“Conceptually, you might think, ‘Who would do something so stupid?’” – Elliot Fishman, MD, of Johns Hopkins Medicine in Baltimore, discussing the malicious potential of deepfake X-rays.
“Sadly, young physicians are going to have to be re-educated about what these diseases look like.” — Paul Offit, MD, of the Children’s Hospital of Philadelphia, on the resurgence of childhood diseases. Haemophilus influenzae Type B.
“More than 100 cases have been reported in the last 3 weeks.” – U.S. Army Lt. Col. Joan McGovern (ret.), of the Yale School of Public Health’s Measles Data Tracking Project, discussing Utah as a measles hotspot.
“It seems to be the most promising alternative to antibiotics.” – Stephanie Strathdee, PhD, of the University of California San Diego, highlights the success of experimental bacteriophage therapy for multi-drug resistant infections in cystic fibrosis patients.
“Imagine our surprise to learn that not only was there less bone turnover, but prednisolone also caused patients to lose weight and their HbA1c improved.” – Karim Miran, MD, of Imperial College London, on a trial favoring prednisolone in place of hydrocortisone for maintaining bone health in adrenal insufficiency.
“Influential promotion can shape demand for a drug, blur the line between personal experience and advertising, and potentially contribute to inappropriate use.” —Rafael Heise, PhD, of the MCI Management Center Innsbruck in Austria, on the lack of transparency in social media posts promoting prescription drugs.
“This has a huge impact on public health.” -Mark Taylor, MD, of an Edinburgh practice in Scotland, found that people with pre-existing depression or anxiety were less likely to have worsening mental health while taking a GLP-1 drug.
“The things that are reported are exaggerated.” —Andrew Gelman, PhD, of Columbia University in New York City, discussing standard clinical trial statistics and Bayesian methods.
“I guess this won’t work.” – Matthew Johnson, PhD, of the Johns Hopkins University School of Medicine, suggests considering what participants who took a placebo during a psychedelic trial for depression might have thought.
